Neurocrine Biosciences announced a $2.9 billion all‑cash acquisition of Soleno Therapeutics, paying $53 per share— a 34% premium to Soleno’s April 2 closing price and a 51% premium to its 30‑day volume‑weighted average price. The transaction is expected to close within 90 days, subject to customary regulatory approvals and other conditions.
The deal adds Soleno’s VYKAT XR, the first FDA‑approved therapy for hyperphagia in Prader‑Willi syndrome, to Neurocrine’s portfolio. VYKAT XR generated $190 million in 2025 revenue, including $92 million in the fourth quarter, and Soleno’s Q4 2025 revenue of $91.7 million reflected a 40% sequential growth from Q3 2025. The acquisition positions Neurocrine in a $1.2 billion treatment market that is projected to reach $2.5 billion by 2032, providing a new revenue stream beyond its legacy products INGREZZA and CRENESSITY.
Soleno reported profitability in 2025, with a net income of $20.9 million and operating cash flow of $48.7 million in Q4 2025. The company’s strong early adoption and over 80% reimbursement coverage for dispensed scripts in Q4 2025 underpin the growth trajectory of VYKAT XR. However, a securities fraud class‑action lawsuit filed against Soleno in March 2025 alleges violations of the Securities Exchange Act of 1934 related to its Phase 3 clinical trial program for DCCR, adding a legal risk to the transaction.
Neurocrine’s Q4 2025 net product sales reached $798.3 million, a 29% year‑over‑year increase, and full‑year 2025 net product sales totaled $2.83 billion, up 22% year‑over‑year. The addition of VYKAT XR is expected to accelerate revenue growth and diversify Neurocrine’s revenue base, aligning with the company’s strategy to move beyond a single‑product focus and expand into rare‑disease endocrinology.
Management highlighted the strategic fit: CEO Kyle Gano said VYKAT XR “holds blockbuster peak sales potential” and will “immediately provide another revenue source.” Business development chief Samir Siddhanti noted that Soleno’s focus at the intersection of neurology and endocrinology “couldn't be a better strategic fit” for Neurocrine, while Soleno CEO Anish Bhatnagar emphasized that Neurocrine’s experience in rare disease and endocrinology would “expand the reach of VYKAT XR in the Prader‑Willi syndrome community.”
Market reaction to the announcement was muted; Neurocrine’s stock fell about 2% in early trading. Analysts on the call questioned the long‑term prospects of VYKAT XR, suggesting that the valuation may be high relative to the drug’s projected sales trajectory, which tempered investor enthusiasm despite the strategic fit.
The acquisition underscores Neurocrine’s broader M&A trend, as the company seeks to diversify its therapeutic portfolio and capture growth in high‑margin rare‑disease markets. The deal also highlights the importance of due diligence in the presence of pending litigation, as the Soleno lawsuit could impact post‑acquisition integration and valuation.
The transaction represents a significant shift in Neurocrine’s business model, adding a high‑growth specialty‑drug platform to its existing product line and positioning the company for accelerated growth beyond its legacy single‑product focus.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.